Updated:
SilverMill
SilverMill is a private investment firm led by a seasoned management team. The team partners with business owners to facilitate ownership transactions and...
SilverMill
SilverMill is a private investment firm led by a seasoned management team. The team partners with business owners to facilitate ownership transactions and support growth through strategic investments and scale expansion.
General information
Firm type
Private Equity
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Isle of Palms
Corporate office
31 25th Avenue, Isle of Palms, SC 29451, United States
Principals
Al Jurgela
Co-Founder & Managing Member
Sector focus
Frequently asked questions
Who runs investment decisions at SilverMill?
Al Jurgela, Co-Founder and Managing Member, leads investment and operational decisions. Jurgela co-founded the firm with the late Ted Pulkownik and appears as the sole named managing principal on the firm's current website.
How does SilverMill structure its acquisitions?
SilverMill requires a larger permanent capital structure and uses platform-company vehicles to aggregate niche suppliers. TCP Analytical, formed with PNC Riverarch Capital, is the main platform through which SilverMill makes lab-supply acquisitions — it later brought in Audax Strategic Capital as a co-investor.
Does SilverMill operate as a single family office or a private equity firm?
SilverMill operates as a private equity firm, not a single family office. There is no public disclosure of a family wealth source backing the firm; its capital appears to come from institutional co-investors and sponsors such as PNC Riverarch Capital and Audax.
What deal types does SilverMill target?
The firm pursues control buyouts and growth-stage investments in companies that provide materials, equipment, and services to the life sciences sector. Its focus is on lab consumables, high-purity chemicals, and custom manufacturing, often acquiring founder-owned businesses and integrating them into larger platforms.
Which sectors does SilverMill explicitly avoid?
SilverMill does not invest in therapeutics discovery, clinical-stage biotech, or healthcare services delivery. It limits its scope to tools and supplies for research and production applications in bioengineering, food safety, in vitro diagnostics, and related technologies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: